Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
Go back to Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer| (AMEX: MKKGY) | Delayed: 30.56 -0.19 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.75 | 52 Week High | $ | |||
| Open | $30.47 | 52 Week Low | $ | |||
| Day High | $30.57 | P/E | N/A | |||
| Day Low | $30.38 | EPS | $ | |||
| Volume | 112,453 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 115.48 +1.61 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.87 | 52 Week High | $65.46 | |||
| Open | $113.97 | 52 Week Low | $47.97 | |||
| Day High | $115.63 | P/E | 78.56 | |||
| Day Low | $113.00 | EPS | $1.47 | |||
| Volume | 10,593,825 | |||||
